Heather A Cubie1, David Morton2, Edson Kawonga3, Mike Mautanga3, Ipyana Mwenitete3, Ngari Teakle3, Bagrey Ngwira4, Hilary Walker5, Graeme Walker5, Savel Kafwafwa2, Beatrice Kabota2, Reynier Ter Haar2, Christine Campbell6. 1. Global Health Academy, University of Edinburgh, 1 George Sq, Edinburgh EH8 9JZ, United Kingdom. Electronic address: Heather.Cubie@ed.ac.uk. 2. Nkhoma CCAP Hospital, PO Box 48, Nkhoma, Central Malawi, Malawi. 3. Nkhoma Hospital Laboratory, PO Box 48, Nkhoma, Central Malawi, Malawi. 4. University of Malawi-The Polytechnic, Department of Community Health, Chichiri, Blantyre 3, Malawi. 5. Department of Obstetrics and Gynaecology, Royal Infirmary of Edinburgh, 51 Little France Cres, Edinburgh EH16 4SA, United Kingdom. 6. Usher Institute for Population Health Sciences & Informatics, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, United Kingdom.
Abstract
BACKGROUND AND OBJECTIVES: Early experience with Cepheid Xpert® HPV assay (Xpert® HPV) suggests that its quick turnaround time and ease of application might make it a relevant contender for routine use in low and middle income countries (LMICs). In the context of a cervical screening service in rural Malawi, we aimed to assess practicalities of local laboratory testing with Xpert® HPV and provide preliminary high-risk HPV (HR-HPV) prevalence data. STUDY DESIGN: Liquid-based cytology (LBC) specimens were collected from women attending cervical screening clinics in Nkhoma, Malawi. Xpert® HPV testing was carried out according to manufacturer's instructions. Partial genotyping results were obtained immediately (HPV 16, 18/45 and HR-HPV 'other'). Review of individual channel data provided further breakdown of other HR-HPV types into HPV 31 and related; HPV 51/59 and HPV 39 and related. RESULTS: Valid HR-HPV results were obtained from 750/763 samples. Most samples were from previously unscreened women, with 92.3% aged between 20 and 60 years. Overall HR-HPV positivity was 19.9%, with HR-HPV 'other' being more than twice as frequent as HPV 16 or HPV 18/45 and HPV 31-related (HPV 31, 33, 35, 52 or 58) most prevalent. Known HIV status was low (7.3%), but HR-HPV positivity in this group was much higher (43.4%). CONCLUSIONS: HR-HPV testing using Xpert® HPV was practical in a small rural laboratory. The rapid turnaround (within 2h) could facilitate a 'see and treat' programme. Partial genotyping allows assessment of risk beyond HPV 16/18. The high prevalence of HPV 31 and related types warrants further investigation.
BACKGROUND AND OBJECTIVES: Early experience with Cepheid Xpert® HPV assay (Xpert® HPV) suggests that its quick turnaround time and ease of application might make it a relevant contender for routine use in low and middle income countries (LMICs). In the context of a cervical screening service in rural Malawi, we aimed to assess practicalities of local laboratory testing with Xpert® HPV and provide preliminary high-risk HPV (HR-HPV) prevalence data. STUDY DESIGN: Liquid-based cytology (LBC) specimens were collected from women attending cervical screening clinics in Nkhoma, Malawi. Xpert® HPV testing was carried out according to manufacturer's instructions. Partial genotyping results were obtained immediately (HPV 16, 18/45 and HR-HPV 'other'). Review of individual channel data provided further breakdown of other HR-HPV types into HPV 31 and related; HPV 51/59 and HPV 39 and related. RESULTS: Valid HR-HPV results were obtained from 750/763 samples. Most samples were from previously unscreened women, with 92.3% aged between 20 and 60 years. Overall HR-HPV positivity was 19.9%, with HR-HPV 'other' being more than twice as frequent as HPV 16 or HPV 18/45 and HPV 31-related (HPV 31, 33, 35, 52 or 58) most prevalent. Known HIV status was low (7.3%), but HR-HPV positivity in this group was much higher (43.4%). CONCLUSIONS:HR-HPV testing using Xpert® HPV was practical in a small rural laboratory. The rapid turnaround (within 2h) could facilitate a 'see and treat' programme. Partial genotyping allows assessment of risk beyond HPV 16/18. The high prevalence of HPV 31 and related types warrants further investigation.
Authors: Louise Kuhn; Rakiya Saidu; Rosalind Boa; Ana Tergas; Jennifer Moodley; David Persing; Scott Campbell; Wei-Yann Tsai; Thomas C Wright; Lynette Denny Journal: Lancet Glob Health Date: 2020-02 Impact factor: 26.763
Authors: Marie-Aimee Muhimpundu; Fidele Ngabo; Felix Sayinzoga; Jean Paul Balinda; John Rusine; Sardis Harward; Arielle Eagan; Sara Krivacsy; Alice Bayingana; Jean Claude Uwimbabazi; Jean Damascene Makuza; Jean de Dieu Ngirabega; Agnes Binagwaho Journal: JCO Glob Oncol Date: 2021-04
Authors: Margot Kunckler; Fanny Schumacher; Bruno Kenfack; Rosa Catarino; Manuela Viviano; Eveline Tincho; Pierre-Marie Tebeu; Liliane Temogne; Pierre Vassilakos; Patrick Petignat Journal: Cancer Med Date: 2017-06-04 Impact factor: 4.452
Authors: Philip E Castle; John E Varallo; Margaret Mary Bertram; Bakgaki Ratshaa; Moses Kitheka; Kereng Rammipi Journal: PLoS One Date: 2020-02-13 Impact factor: 3.240